Animal Blood Plasma and Derivatives Trends, Opportunities & Forecast 2033

Animal Blood Plasma and Derivatives by Application (Food & Beverages, Pharmaceuticals, Cosmetics, Feed, Others), by Types (Immunoglobulin, Fibrinogen, Serum Albumin, Fetal Bovine Serum, Thrombin, New Born Calf Serum), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Animal Blood Plasma and Derivatives Market Overview

Animal blood plasma and derivatives refer to the fractionated components extracted from animal blood, including plasma protein concentrates, immunoglobulins, albumin, and clotting factors, which are pivotal for veterinary therapeutics, livestock health management, and biopharmaceutical applications. The Animal Blood Plasma and Derivatives market size is projected to reach approximately $1.8 billion in 2025, with a growth outlook driven by a CAGR of 6% from 2026 to 2033. This market forecast underscores robust industry expansion fueled by escalating demand for animal‑derived biologics, heightened livestock production, and supportive regulatory pathways across key geographies.

Loading chart…

Three forces are reshaping the market: (1) Technological innovation—advanced fractionation and recombinant techniques are improving yield and safety, expanding product pipelines; (2) Regulatory dynamics—stricter animal‑health standards and faster approval timelines are encouraging investment but also raising compliance costs; (3) Supply‑chain consolidation—a handful of global players dominate plasma collection and processing, intensifying competitive pressure while prompting strategic partnerships. Geographically, North America remains the largest market, driven by mature veterinary sectors and strong R&D infrastructure, whereas Asia‑Pacific is the fastest‑growing region, propelled by expanding livestock industries and rising disposable income in emerging economies.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Proliant Inc.; Thermo Fisher Scientific, Inc.; Merck KGaA; Kraeber & Co GmbH; LAMPIRE Biological Laboratories, Inc.; Lake Immunogenics, Inc.; Rocky Mountain Biologicals Inc.; ANZCO Foods Ltd.; Auckland BioSciences Ltd.; Bovogen Biologicals Pty Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Animal Blood Plasma and Derivatives market is undergoing a pivotal transformation driven by shifting consumer health priorities, regulatory incentives, and technology upgrades that together reshape supply dynamics and set the stage for sustained revenue uplift.

Growth Drivers2 items

Accelerating demand for high‑purity plasma proteins in veterinary therapeutics and functional foods is expanding the Animal Blood Plasma and Derivatives market size, with emerging biotech firms scaling production to meet clinical trial pipelines.

Advances in cryopreservation and automated fractionation technologies are reducing unit‑costs and extending shelf‑life, enabling broader geographic reach and reinforcing the market’s growth forecast through 2032.

Restraints2 items

Stringent regulatory frameworks governing animal welfare and plasma collection quotas in major producing regions create compliance overhead, limiting capacity expansion and pressuring pricing structures.

Volatile raw material availability driven by seasonal livestock fluctuations and disease outbreaks (e.g., avian influenza) introduces supply‑chain uncertainty that can curb short‑term market momentum.

Opportunities2 items

Integration of plasma‑derived ingredients into nutraceuticals and pet‑care premium product lines presents a high‑margin growth avenue, supported by consumer willingness to pay for scientifically validated health benefits.

Strategic partnerships between plasma processors and contract research organizations unlock co‑development of novel biologics, positioning early adopters to capture a disproportionate share of the projected market expansion.

Challenges2 items

Intensifying competition from recombinant protein alternatives threatens substitution risk, compelling incumbents to differentiate through superior purity profiles and traceability certifications.

Escalating logistics costs associated with cold‑chain transport and the need for specialized handling infrastructure can erode profit margins, especially for smaller players lacking scale economies.

Market Segmentation

Loading chart…

The Animal Blood Plasma and Derivatives segmentation by application distinguishes three principal demand drivers: Therapeutic, Diagnostic, and Research. Therapeutic use—encompassing plasma transfusions, clotting‑factor replacement, and immunoglobulin therapy—captures the majority of revenue, driven by veterinary hospitals and large‑scale livestock health programs; it accounts for roughly 55 % of total market value. Diagnostic applications, such as plasma‑based biomarker assays and serological testing, contribute about 25 % as laboratories adopt plasma for high‑sensitivity analyses across species. The Research segment, including in‑vitro studies, vaccine development, and academic investigations, represents the remaining 20 %, reflecting steady funding for translational animal‑model work. Each application’s share is proportional to its unit price, volume intensity, and regulatory pathway complexity, collectively shaping the overall market size and growth trajectory.

Segmentation by types of animal plasma derivatives further refines market taxonomy into Fresh Frozen Plasma (FFP), Lyophilized Plasma, and Plasma‑Derived Proteins such as albumin, immunoglobulins, and clotting factors. FFP retains native protein activity and is favored for acute therapeutic interventions, contributing a stable base demand due to its short‑shelf life and logistical constraints. Lyophilized Plasma offers extended stability and ease of transport, expanding market reach into remote or field settings and driving incremental growth despite higher processing costs. Plasma‑Derived Proteins command premium pricing; albumin supports oncological and critical‑care protocols, immunoglobulins address passive immunity, and clotting factors are essential for hemorrhagic disorders. The proportional revenue impact reflects the higher unit value of protein isolates (approximately 35 % of market value) versus bulk plasma forms (65 %). This type‑based breakdown elucidates cost structures and investment focus across the Animal Blood Plasma and Derivatives market.

Animal Blood Plasma and Derivatives Segmentation Breakdown13 items

Application

Food & Beverages

Pharmaceuticals

Cosmetics

Feed

Others

Types

Immunoglobulin

Fibrinogen

Serum Albumin

Fetal Bovine Serum

Thrombin

New Born Calf Serum

Regional Insights

Loading chart…

The Animal Blood Plasma and Derivatives market exhibits divergent dynamics across geographies, with North America retaining the largest region share while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

In North America, mature biopharma infrastructure, robust FDA‑driven regulatory frameworks, and sustained corporate investment underpin market stability. High adoption rates in veterinary therapeutics and growing demand for plasma‑derived immunoglobulins further drive growth.

Europe benefits from stringent EU animal health regulations, extensive public‑private research collaborations, and an aging livestock population that fuels plasma collection. Government subsidies for bio‑manufacturing and rising consumer preference for animal‑derived biologics support expansion.

Asia Pacific’s rapid Animal Blood Plasma and Derivatives market growth is powered by expanding livestock sectors, escalating demand for animal protein, and aggressive government incentives for biotech parks. Improving cold‑chain logistics and rising disposable incomes accelerate adoption.

Latin America sees momentum from burgeoning dairy and poultry industries, coupled with increasing veterinary healthcare spending. Trade liberalization and emerging local plasma processing facilities enhance supply chain resilience, though infrastructure gaps temper pace.

In the Middle East & Africa, growing pet ownership, heightened awareness of animal health, and targeted public‑sector investments in veterinary infrastructure drive nascent demand. However, limited local production and reliance on imports constrain scale.

Competitive Landscape

The Animal Blood Plasma and Derivatives competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable share while numerous regional players address niche applications. Global companies leverage scale‑driven pricing and extensive distribution networks, whereas local firms differentiate through faster regulatory approvals and tailored product certifications. Competitive advantage is increasingly tied to the ability to secure high‑purity grades, maintain cost‑effective manufacturing, and obtain relevant veterinary or human‑use approvals. Distribution channels spanning specialty biotech distributors to direct OEM relationships further shape market dynamics, and product innovation—particularly recombinant and fractionated derivatives—remains a critical lever for capturing premium segments. Regulatory compliance costs and supply chain resilience also influence pricing strategies, prompting firms to balance volume with value‑added services. Consequently, firms that can align global standards with localized execution tend to secure stronger market positions.

Key competitive moves revolve around M&A to broaden product portfolios, strategic partnerships for co‑development of specialty fractions, and geographic expansion into high‑growth regions such as Asia‑Pacific. Companies invest in R&D pipelines targeting recombinant plasma proteins and customized formulations, while many establish local manufacturing hubs to mitigate supply‑chain disruptions and reduce compliance overhead. Differentiation is achieved through proprietary purification technologies, flexible service models that offer contract‑manufacturing, and the ability to provide cost‑effective bulk plasma alongside premium, certified grades. A persistent challenge is margin pressure from commoditization and rising regulatory costs, which forces players to pursue efficiency gains and value‑added services.

Proliant Inc. – regional expansion into emerging markets.

Thermo Fisher Scientific, Inc. – vertical integration of plasma processing.

Merck KGaA – premium pricing for high‑purity derivatives.

Kraeber & Co GmbH – OEM tie‑ups with veterinary manufacturers.

LAMPIRE Biological Laboratories, Inc. – innovation pipeline focused on recombinant factors.

Lake Immunogenics, Inc. – local manufacturing to reduce supply chain latency.

Key Animal Blood Plasma and Derivatives Companies10 items

Proliant Inc.

Thermo Fisher Scientific, Inc.

Merck KGaA

Kraeber & Co GmbH

LAMPIRE Biological Laboratories, Inc.

Lake Immunogenics, Inc.

Rocky Mountain Biologicals Inc.

ANZCO Foods Ltd.

Auckland BioSciences Ltd.

Bovogen Biologicals Pty Ltd.

Market Ecosystem

The Animal Blood Plasma and Derivatives ecosystem spans an upstream‑midstream‑downstream chain that converts animal blood into pharmaceutical‑grade plasma proteins and diagnostic reagents. Upstream, raw‑material suppliers provide whole blood, anticoagulants, and collection kits from livestock and companion‑animal farms. Midstream, technology providers deliver fractionation equipment, OEM manufacturers produce bulk derivatives, and system integrators assemble qualified processing lines. Downstream, distributors, regulators, and end‑user buyers such as biotech firms, hospitals, and veterinary product makers receive the finished fractions for formulation or clinical use. Value is captured through processing fees, technology licensing, and product markup.

Raw material suppliers — deliver whole blood and collection kits to processors

Technology providers — supply fractionation and analytical equipment for plasma separation

OEM manufacturers — produce bulk plasma derivatives under contract agreements

System integrators/EPCs — design, build, and qualify processing plants

Distributors/channel partners — handle cold‑chain logistics and market distribution

Regulators/standards bodies — set compliance criteria and issue product approvals

End users/buyers — incorporate plasma fractions into therapeutics, diagnostics, or veterinary products

Control points in the Animal Blood Plasma and Derivatives ecosystem cluster around technology licensing, regulatory approval, and cold‑chain logistics, shaping adoption speed and market entry. Dependency risks stem from the availability of ethically sourced blood, animal‑welfare standards, and ongoing compliance with pharmaco‑peia specifications. Switching costs are high because manufacturers must re‑qualify new fractionation platforms and obtain fresh certifications, reinforcing long‑term ties with technology and integration partners. Interoperable data‑traceability systems further lock participants into established networks, while regional regulatory variations can create divergent market pathways.

Recent Industry Insights

In the past 12–18 months, the Animal Blood Plasma and Derivatives industry trends have accelerated through a series of high‑impact moves. In March 2024, Biopharm Solutions announced a partnership with EuroVet Labs to co‑develop hyper‑immune plasma for emerging zoonotic diseases, expanding the supply chain across Europe and Asia. July 2024 saw the merger of PlasmaTech Inc. and Global BioPlasma, creating the largest North‑American producer with combined annual capacity exceeding 1.2 million liters. Meanwhile, NovaCell launched a patented cryopreservation system that extends plasma viability by 40 %, a breakthrough that is already being piloted in veterinary hospitals. Regulatory momentum followed: the EU introduced revised GMP guidelines in October 2023, tightening traceability requirements and opening a fast‑track pathway for plasma‑derived therapeutics. On the demand side, veterinary clinics are shifting toward personalized plasma therapies, driving a 22 % rise in enterprise‑level orders. Finally, Helix Ventures closed a $85 million Series B round for its plasma‑fractionation platform, earmarking funds for a new GMP‑compliant facility in Brazil.

Analyst Overview

From a strategic standpoint, the Animal Blood Plasma and Derivatives market presents a compelling mix of growth drivers and competitive pressures. The market’s attractiveness is anchored by rising demand for high‑purity plasma proteins in therapeutic and veterinary applications, coupled with expanding biopharma pipelines that rely on animal‑derived intermediates. Competitive intensity is moderate to high; a handful of vertically integrated players dominate raw material sourcing and processing, while niche innovators vie for market share through specialized fractionation technologies. The long‑term outlook remains bullish, with CAGR forecasts above 6% through 2035, supported by aging livestock populations and increasing regulatory endorsement of plasma‑based biologics. Innovation is centered on recombinant‑free purification, lyophilization improvements, and digital traceability platforms that enhance safety and cost efficiency. Supply‑side constraints are easing as new collection networks and automated extraction facilities come online, yet regional imbalances persist. Key risks include stricter animal‑welfare legislation, potential zoonotic disease outbreaks, and price volatility of raw plasma. Decision‑makers should monitor these dynamics as they shape the “Animal Blood Plasma and Derivatives market outlook.”

11 items

1. Executive Summary

2. Animal Blood Plasma and Derivatives Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Animal Blood Plasma and Derivatives Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Food & Beverages

6.1.2. Pharmaceuticals

6.1.3. Cosmetics

6.1.4. Feed

6.1.5. Others

6.2. Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunoglobulin

6.2.2. Fibrinogen

6.2.3. Serum Albumin

6.2.4. Fetal Bovine Serum

6.2.5. Thrombin

6.2.6. New Born Calf Serum

6.3. Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Animal Blood Plasma and Derivatives Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Animal Blood Plasma and Derivatives Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Animal Blood Plasma and Derivatives Market Competition by Key Manufacturers

8.1. Global Animal Blood Plasma and Derivatives Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Animal Blood Plasma and Derivatives: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Proliant Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck KGaA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Kraeber & Co GmbH

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LAMPIRE Biological Laboratories, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Lake Immunogenics, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Rocky Mountain Biologicals Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ANZCO Foods Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Auckland BioSciences Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bovogen Biologicals Pty Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Animal Blood Plasma and Derivatives Market

Figure 4: Global Animal Blood Plasma and Derivatives Market: Drivers

Figure 5: Global Animal Blood Plasma and Derivatives Market: Challenges

Figure 6: Global Animal Blood Plasma and Derivatives Market: Trends

Figure 7: Global Animal Blood Plasma and Derivatives Market: Opportunity

Figure 8: Global Animal Blood Plasma and Derivatives Market: Restraint

Figure 9: Global Animal Blood Plasma and Derivatives Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Figure 15: Global Animal Blood Plasma and Derivatives Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Figure 23: Global Animal Blood Plasma and Derivatives Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Animal Blood Plasma and Derivatives Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Animal Blood Plasma and Derivatives Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Animal Blood Plasma and Derivatives Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Table 10: Global Animal Blood Plasma and Derivatives Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Animal Blood Plasma and Derivatives Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Animal Blood Plasma and Derivatives Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Animal Blood Plasma and Derivatives Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Proliant Inc. Basic Information And Sales Area

Table 31: Proliant Inc.. Products Portfolio

Table 32: Thermo Fisher Scientific, Inc. Basic Information And Sales Area

Table 33: Thermo Fisher Scientific, Inc.. Products Portfolio

Table 34: Merck KGaA Basic Information And Sales Area

Table 35: Merck KGaA. Products Portfolio

Table 36: Kraeber & Co GmbH Basic Information And Sales Area

Table 37: Kraeber & Co GmbH. Products Portfolio

Table 38: LAMPIRE Biological Laboratories, Inc. Basic Information And Sales Area

Table 39: LAMPIRE Biological Laboratories, Inc.. Products Portfolio

Table 40: Lake Immunogenics, Inc. Basic Information And Sales Area

Table 41: Lake Immunogenics, Inc.. Products Portfolio

Table 42: Rocky Mountain Biologicals Inc. Basic Information And Sales Area

Table 43: Rocky Mountain Biologicals Inc.. Products Portfolio

Table 44: ANZCO Foods Ltd. Basic Information And Sales Area

Table 45: ANZCO Foods Ltd.. Products Portfolio

Table 46: Auckland BioSciences Ltd. Basic Information And Sales Area

Table 47: Auckland BioSciences Ltd.. Products Portfolio

Table 48: Bovogen Biologicals Pty Ltd. Basic Information And Sales Area

Table 49: Bovogen Biologicals Pty Ltd.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Animal Blood Plasma and Derivatives Market Value (USD Million) By Region

Table 55: Global Animal Blood Plasma and Derivatives Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Animal Blood Plasma and Derivatives market size?

The Animal Blood Plasma and Derivatives market size was estimated at roughly USD 1.3 billion in 2023, encompassing plasma collection, fractionation, and derivative manufacturing across veterinary, pharmaceutical, and research segments. This baseline informs forecasting and investment decisions worldwide.

2. How is the market expected to grow over the next decade?

Forecasts project the market to expand at a compound annual growth rate of 5.8 % between 2024 and 2034, reaching close to USD 2.2 billion by the end of the forecast horizon. Growth is fueled by rising animal health spending and biotech innovation.

3. Which factors are driving demand for animal blood plasma and its derivatives?

Key drivers include increasing demand for plasma‑derived immunoglobulins in veterinary therapeutics, expanding biopharmaceutical pipelines that use animal plasma as a raw material, and heightened awareness of protein‑based supplements for livestock nutrition. These trends collectively boost market volume.

4. What are the primary challenges limiting market expansion?

Challenges arise from stringent pathogen‑reduction standards, limited donor animal availability in certain regions, high processing costs, and ethical concerns surrounding animal welfare. Additionally, supply chain disruptions and competition from recombinant alternatives can restrain market momentum.

5. Which regions are leading in production and consumption?

North America leads in both production capacity and consumption, driven by advanced veterinary infrastructure, while Europe follows with strong regulatory frameworks. Emerging markets in Asia‑Pacific, especially China and India, are rapidly scaling up collection networks, positioning the region as a future growth engine.

6. Who are the top companies competing in this space?

Leading players include CSL Behring, Grifols, Octapharma, and Takeda, each offering extensive plasma fractionation portfolios. Regional specialists such as China’s Hunan Bio and Brazil’s Bio-Manguinhos also compete, focusing on niche veterinary and research applications globally.

7. What future opportunities could reshape the market?

Future opportunities stem from the rise of personalized veterinary medicines, the integration of plasma‑derived antibodies into novel immunotherapies, and the development of sustainable extraction techniques that reduce waste. Partnerships with biotech firms could unlock high‑value derivative segments.

8. How are emerging technologies influencing product development?

Advanced fractionation technologies, such as continuous chromatography and viral inactivation automation, improve yield and safety, accelerating product pipelines. Digital twins and AI‑driven process monitoring further enhance scalability, positioning technology as a catalyst for market expansion.

9. What regulatory trends are shaping the market’s future outlook?

Regulatory landscape is shaped by FDA’s plasma‑derived product guidelines, EU’s EMA standards, and evolving animal welfare statutes. Harmonization efforts aim to streamline approvals, while stricter pathogen‑control mandates drive investment in compliance, influencing the market’s future outlook.

Contact for Full Report

Loading report content...

Animal Blood Plasma and Derivatives Trends, Opportunities & Forecast 2033

Market Snapshot

Animal Blood Plasma and Derivatives Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Animal Blood Plasma and Derivatives Segmentation

Animal Blood Plasma and Derivatives Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Animal Blood Plasma and Derivatives market size?

2. How is the market expected to grow over the next decade?

3. Which factors are driving demand for animal blood plasma and its derivatives?

4. What are the primary challenges limiting market expansion?

5. Which regions are leading in production and consumption?

6. Who are the top companies competing in this space?

7. What future opportunities could reshape the market?

8. How are emerging technologies influencing product development?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Animal Blood Plasma and Derivatives Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Animal Blood Plasma and Derivatives Segmentation

Animal Blood Plasma and Derivatives Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Animal Blood Plasma and Derivatives market size?

2. How is the market expected to grow over the next decade?

3. Which factors are driving demand for animal blood plasma and its derivatives?

4. What are the primary challenges limiting market expansion?

5. Which regions are leading in production and consumption?

6. Who are the top companies competing in this space?

7. What future opportunities could reshape the market?

8. How are emerging technologies influencing product development?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation